ArticleThoracic cancer2024
Risk factors for lung parenchyma hemorrhage and hemoptysis during computed tomography-guided microwave ablation in patients with stage I non-small cell lung cancer: A bicentric retrospective study.
Article in Thoracic cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Synchronous percutaneous microwave ablation combined with percutaneous biopsy for highly suspected malignant pulmonary nodules: a retrospective study.Journal of thoracic disease · 2025Article
- Risk factors for lung parenchyma hemorrhage and hemoptysis during computed tomography-guided microwave ablation in patients with stage I non-small cell lung cancer: A bicentric retrospective study.Thoracic cancer · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThis study aimed to identify the risk factors for lung parenchyma hemorrhage and hemoptysis during computed tomography-guided microwave ablation (MWA) in patients with stage I non-small cell lung cancer (NSCLC).
methodsA total of 417 patients from two medical centers were included, of whom 353 were from center 1 and 64 were from center 2. The risk factors for lung parenchyma hemorrhage and hemoptysis were selected by univariable and multivariable logistic analyses in the center 1 dataset. The selected risk factors were validated in the center 2 dataset.
resultsThe risk factors for lung parenchyma hemorrhage during MWA were focal blood supplies (odds ratio [OR], 2.602; 95% confidence interval [CI], 1.609-4.210; p < 0.001), near vessels larger than 2 mm (OR, 4.145; 95% CI, 1.963-8.755; p < 0.001), and traversing vessels in the track of ablation (OR, 2.961; 95% CI, 1.492-5.874; p = 0.002). The risk factors for hemoptysis were lung parenchyma hemorrhage (OR, 34.165; 95% CI, 12.255-95.247; p < 0.001), needle track traversing the lung parenchyma by >25 mm (OR, 4.494; 95% CI, 1.833-11.018; p = 0.001), and traversing vessels in the track of ablation (OR, 5.402; 95% CI, 2.269-12.865; p < 0.001).
conclusionsFocal blood supplies, near vessels larger than 2 mm, and traversing vessels in the track of ablation were independent risk factors for lung parenchyma hemorrhage during MWA. Lung parenchyma hemorrhage, needle track traversing the lung parenchyma by >25 mm, and traversing vessels in the track of ablation were independent risk factors for hemoptysis during MWA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.